Bax mRNA therapy using cationic liposomes for human malignant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Bax is a pro-apoptotic protein and tumor suppressor.
• Gene therapy using Bax has been explored for cancer treatment.
• Messenger RNA (mRNA) lipofection offers enhanced gene transfer efficiency over plasmid DNA.

Purpose of the Study:

• To evaluate the anti-tumor efficacy of Bax mRNA lipofection in human malignant melanoma cells.
• To compare the effectiveness of Bax mRNA lipofection with Bax plasmid gene therapy.

Main Methods:

• In vitro assessment of Bax protein expression, cell growth inhibition, caspase-3 activity, and apoptosis.
• In vivo administration of liposome-Bax mRNA to nude mice with human malignant melanoma xenografts.
• Tumor volume measurement and TUNEL assay for apoptosis detection.

Main Results:

• Bax mRNA lipofection significantly increased Bax protein expression, caspase-3 activity, and apoptosis.
• Liposome-Bax mRNA treatment resulted in substantial inhibition of tumor growth in mice.
• Bax plasmid transfer showed minimal impact on tumor growth compared to controls.

Conclusions:

• Bax mRNA therapy delivered via liposomes exhibits stronger anti-tumor activity than traditional Bax plasmid gene therapy.
• Bax mRNA lipofection represents a promising therapeutic strategy for malignant melanoma.